FENNEC PHARMACEUTICALS INC.

FENC

Held by 0 specialist biotech funds

Short interest: 3.5% of float.

BiotechnologyCEO: Jeffrey S. HackmanIPO: 2017Website ↗

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

FENNEC PHARMACEUTICALS INC.

Signal Score

Fund Holdings

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Research Links

Related Research